Previous close | 938.00 |
Open | 950.00 |
Bid | 973.90 x 0 |
Ask | 974.00 x 0 |
Day's range | 939.00 - 976.45 |
52-week range | 850.00 - 1,083.00 |
Volume | |
Avg. volume | 2,663,848 |
Market cap | 786.655B |
Beta (5Y monthly) | 0.43 |
PE ratio (TTM) | 31.25 |
EPS (TTM) | 31.17 |
Earnings date | 10 May 2022 |
Forward dividend & yield | 5.00 (0.52%) |
Ex-dividend date | 09 Aug 2021 |
1y target est | 1,076.05 |
Cipla Limited (BSE: 500087) (NSE: CIPLA EQ) (hereafter referred to as "Cipla") today announced that it has received final approval for its Abbreviated New Drug Application (ANDA) for Difluprednate Ophthalmic Emulsion 0.05% from the United States Food and Drug Administration (US FDA).
Cipla Limited (BSE: 500087) (NSE: CIPLA EQ) (hereafter referred to as "Cipla") today announced that it has received final approval for its Abbreviated New Drug Application (ANDA) for Arformoterol Tartrate Inhalation Solution 15 mcg / 2 mL from the United States Food and Drug Administration (US FDA).